Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.
Chan, A., Anbuselvan, A., Upadhyayula, S., Jemimah, S., Jaynes, P., Hoppe, M., et al. (2022). Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma. EUROPEAN JOURNAL OF CANCER, 174(22), S55-S56 [10.1016/S0959-8049(22)00949-2].
Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma
Bertolazzi, G.;Tripodo, C.;
2022-01-01
Abstract
Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Chan_Anand_Tripodo_et_al.pdf
accesso aperto
Descrizione: pdf del paper
Tipologia:
Versione Editoriale
Dimensione
73.18 kB
Formato
Adobe PDF
|
73.18 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
